Skip to content
PeptideTech
sign in
live116 compounds · 15 vendors listed · 7 graded · audit of 4 Nov 2026 · prices checked 6 Nov 2026independent · grades can’t be bought

Home / Research library / CJC-1295 (DAC)

Peptides

CJC-1295 (DAC): molecular data, studies & sources

CJC-1295 (DAC) is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C165H269N47O46
Molecular weight (MW)
3647.2 g/mol
PubChem compound ID
91971820
Record title
Cjc 1295

This is the CJC-1295 record with the drug affinity complex (DAC). It must not be used as the molecular identity or clinical evidence for products labeled CJC-1295 without DAC.

Source: PubChem CID 91971820 · retrieved 2026-09-21

2D molecular structure for CJC-1295 (DAC), PubChem CID 91971820
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
InChIKey
ZUQGTWKGESAQCD-ZGFIGYLBSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCNC(=O)CCN3C(=O)C=CC3=O)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC4=CC=C(C=C4)O)N
Machine-readable PubChem source

Identifiers

PubChem CID
91971820
CAS Registry Number
446262-90-4via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII
62RC32V9N7
InChIKey
ZUQGTWKGESAQCD-ZGFIGYLBSA-N

Other names and development codes: CJC-1295

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-07.

Calculated molecular descriptors
Monoisotopic (exact) mass3645.0155 Da
Heavy atoms258
Hydrogen-bond donors54
Hydrogen-bond acceptors50
Rotatable bonds125
Topological polar surface area1542.5 Ų
Calculated logP (Crippen)-14.19
Rings4
Stereocenters33
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drugs@FDA lists no NDA, BLA or ANDA with CJC-1295 as an active ingredient (names searched: CJC-1295; checked October 7, 2026). Research-labelled CJC-1295 (DAC) listings are not FDA-approved drugs.

An FDA approval covers a defined medicine, formulation and labelled use. It does not extend to research-labelled material sold under the same compound name. Identity basis: No INN; the code name CJC-1295 was searched.

Source: Drugs@FDA via openFDA (active-ingredient search for CJC-1295) · checked . openFDA data are not intended for clinical decisions.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list CJC-1295 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched.

By highest phase
Phase 2 · 1
By registry status
Terminated · 1
StudyPhase · statusConditionsSponsor · size
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527 · start 2005-12Phase 2TerminatedObesity · HIV InfectionsConjuChem120 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received CJC-1295, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

  1. Human study · PubMed trial index Compound given to participants

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    Teichman SL, Neale A, Lawrence B et al. · The Journal of clinical endocrinology and metabolism · 2006

    PMID 16352683 · DOI: 10.1210/jc.2005-1536

  2. Human study · PubMed trial index Compound given to participants

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

    Ionescu M, Frohman LA · The Journal of clinical endocrinology and metabolism · 2006

    PMID 17018654 · DOI: 10.1210/jc.2006-1702

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

No additional matching publication was retained. The search links below allow further investigation; they are not evidence that a study exists.

    CJC-1295 (DAC) supplier sources

    Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

    CJC-1295 (DAC) for sale: compare prices, sizes and forms from every tracked supplier →

    SupplierRecorded packagesExample source listing
    Blank PeptidesUSD5mg Vial1 recorded offers5mg Vial · $50.00Stale observation · Checked Sep 30, 2026Supplier listing, CJC-1295 (DAC) 5mg Vial, Blank Peptides, opens in a new tab
    Amino USAUSD2mg Vial1 recorded offers2mg Vial · $25.00Checked Nov 6, 2026Supplier listing, CJC-1295 (DAC) 2mg Vial, Amino USA, opens in a new tab
    Cenexa LabsUSD5mg Vial1 recorded offers5mg Vial · $60.99Checked Nov 6, 2026Supplier listing, CJC-1295 (DAC) 5mg Vial, Cenexa Labs, opens in a new tab

    Reference sources & further reading

    The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

    Search for additional research

    These links run searches; their results have not been individually reviewed and can include unrelated compounds.

    Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

    Related research profiles